



QuantX Biosciences Closes Oversubscribed \$85M Series B Financing

Round co-led by LAV and Sanofi Ventures

PRINCETON, NJ and SHANGHAI, CHINA – [QuantX Biosciences, Inc.](#), a computationally driven drug discovery and development company using advanced modeling and high-performance computing to rapidly design and optimize oral small molecule therapeutics, announced today the close of an oversubscribed \$85 million Series B financing co-led by LAV and Sanofi Ventures. Additional investors included Hongshan, and existing investors.

The proceeds from this financing will be used to support the clinical development of its best-in-class STAT6 oral small molecule inhibitor and IL-17 oral small molecule inhibitor, in addition to continued discovery efforts for oral therapies in immunology and inflammation.

“This fundraising is a watershed moment for QuantX as we continue to refine our strong discovery engine, add to our robust pipeline, and advance multiple programs towards human studies,” said Wei Li, Ph.D., Interim Chief Executive Officer of QuantX and a Founding Partner of Creacion Ventures. “In only three years, we’ve assembled a world-class team that’s been successful in not only discovering multiple, new, first-in-class small molecule candidates for diseases with large patient populations, but have also advanced these to IND-enabling studies.”

David Wang, MD, Ph.D., Partner and Senior Managing Director of OrbiMed, added, “The combination of QuantX’s ability to deliver best-in-class assets and the speed by which they’re able to advance these programs makes for a unique value proposition across a variety of therapeutic indications. We look forward to continuing our support of QuantX as they endeavor to transform the standards of care across a range of diseases.”

QuantX Biosciences was co-founded by veteran drug hunters Wayne Tang, Ph.D. and Yax Sun, Ph.D. in 2022. Since its inception, the company has focused on the development of a world class computational drug discovery platform by merging physics-based and statistical modeling, which has resulted in the development of multiple high quality oral small molecule development candidates.

Previously incubated by OrbiMed and Creacion Ventures, QuantX has raised \$130 million to date.

About QuantX



QuantX Biosciences is a privately held pharmaceutical company advancing oral small-molecule medicines through a computationally driven drug discovery platform. The company integrates physics-based modeling, statistical methods, and computational chemistry to rapidly design and optimize drug candidates against clinically validated targets. QuantX is focused on building a pipeline of differentiated therapies for immune-mediated and inflammatory diseases, with the goal of improving development efficiency and success rates. Headquartered in Princeton, New Jersey, QuantX Biosciences is backed by leading life science investors and a team with deep expertise in drug discovery and development.

QuantX Contact:

Peter Greensmith

QuantX Biosciences

peter.greensmith@quantbio.com

Media Contact

Andrew W. Mielach

LifeSci Communications

amielach@lifescicomms.com



**曲欣生物 (QuantX Biosciences) 完成超额认购的 8,500 万美元 B 轮融资
本轮融资由 礼来亚洲基金 (LAV) 与赛诺菲创投 (Sanofi Ventures) 联合领投**

美国新泽西州普林斯顿市与中国上海——曲欣生物 (QuantX Biosciences, Inc.) 今日宣布，公司已完成一轮超额认购的 8,500 万美元 B 轮融资。本轮融资由礼来亚洲基金 (LAV) 与赛诺菲创投 (Sanofi Ventures) 联合领投，其他投资方包括红杉中国 (Hongshan) 及现有投资人。曲欣生物是一家以计算驱动为核心的药物发现与开发公司，利用先进建模技术和高性能计算平台，加速口服小分子治疗药物的设计与优化。

本轮融资所得资金将用于支持公司同类最佳 (best-in-class) 的 STAT6 口服小分子抑制剂和 IL-17 口服小分子抑制剂的临床开发，同时推进其在免疫与炎症领域口服治疗药物的持续研发工作。



曲欣生物临时首席执行官、Creacion Ventures 创始合伙人李伟博士表示：“此次融资对曲欣生物来说是一个里程碑式的重要时刻。我们将继续完善强大的药物发现引擎，扩展稳健的研发管线，并推动多个项目迈向临床试验阶段。在短短的三年内，我们已组建了一支世界一流的团队，不仅成功发现了多个可用于广大患者群体疾病的全新、同类首创（first-in-class）小分子候选药物，还将其推进至新药临床试验申请研究阶段。”

奥博资本（OrbiMed）全球合伙人和资深董事总经理王国玮（David Wang）医学博士、博士补充道：“曲欣生物公司的独特价值在于其能够高速推进并交付可用于不同治疗领域方向的最佳资产的能力。我们将继续期待并支持曲欣生物，致力于改变一系列疾病的现行标准治疗方案。”

曲欣生物成立于 2022 年，由资深药物研发专家唐海峰博士（Wayne Tang, Ph.D.）和孙亚雄博士（Yax Sun, Ph.D.）共同创立。自成立以来，公司专注于打造世界一流的计算药物发现平台，通过融合基于物理的建模与统计建模方法，已成功开发出多个高质量的口服小分子药物开发候选物。

此前由奥博资本（OrbiMed）与 Creacion Ventures 孵化，截至目前公司累计融资金额已达 1.3 亿美元。

关于曲欣生物

曲欣生物是一家私营制药公司，致力于通过计算驱动的药物发现平台推进口服小分子药物的研发。公司整合基于物理的建模、统计方法和计算化学技术，针对临床验证靶点，快速设计和优化药物候选物。曲欣生物专注于构建差异化的管线用于治疗免疫介导性和炎症性疾病，旨在提升药物开发效率和成功率。公司总部位于美国新泽西州普林斯顿市，背后拥有一流的生命科学投资机构支持，并拥有一支在药物研发领域经验深厚的团队。

曲欣生物联系方式：

Peter Greensmith
QuantX Biosciences
peter.greensmith@quantbio.com

媒体联系方式：

Andrew W. Mielach
LifeSci Communications
amielach@lifescicomms.com

